Davunetide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •2 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 10 community reports
- •1 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Clinical Outcome | A phase 2/3 trial in progressive supranuclear palsy (PSP) failed to show efficacy (Boxer et al., 2014). Earlier studies showed improvements in memory in patients with mild cognitive impairment and functional improvement in schizophrenia. The developer became insolvent. | The small number of community users interested in davunetide focus on its neuroprotective properties for general cognitive health rather than specific disease states. Most are aware of the PSP trial failure but point to the MCI and schizophrenia data as promising. | high The failed PSP trial and developer insolvency significantly weakened the evidence trajectory for davunetide. However, the compound is being re-developed for ADNP syndrome by ExoNavis. |
| Administration Route | Clinical trials used intranasal administration at doses of 5-30 mg twice daily. The intranasal route was chosen for CNS delivery of this neuroprotective peptide. | The few community users primarily use intranasal delivery, matching the clinical route. Some have attempted subcutaneous injection as an alternative. | low Intranasal delivery aligns between clinical and community use. However, pharmaceutical-grade nasal formulations differ from community reconstitution approaches. |
| Dosing | Clinical trials used intranasal davunetide at various doses. The MCI Phase 2 trial used 5 mg once daily or 15 mg twice daily. The Phase 2/3 PSP trial used 30 mg twice daily (60 mg total daily). | Community doses are generally lower (2-5 mg total daily), reflecting cost constraints, limited availability, and caution with a compound that failed a major clinical trial. | moderate Community doses are significantly lower than clinical doses. Whether these lower doses achieve meaningful CNS exposure is unknown. |
Compare these community approaches with published research findings.
Community Protocols
Intranasal Neuroprotective Protocol
Niche- Route
- Intranasal
- Dose
- 2-5 mg
- Frequency
- 1-2 times daily
- Duration
- 4-12 weeks
Adapted from clinical trial intranasal dosing; very few community users have attempted davunetide
Subcutaneous Injection Protocol
Niche- Route
- Subcutaneous
- Dose
- 1-5 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Alternative route for those who prefer injection; not the clinically studied route
Stacking Patterns
Davunetide + Semax Neuroprotective Stack
NicheCombining microtubule stabilization (davunetide) with BDNF upregulation (Semax) for multi-pathway neuroprotection
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 10+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Nootropics|Davunetide/NAP peptide discussions (limited)(accessed 2026-02-16)
- Reddit r/Peptides|Davunetide neuroprotective peptide threads(accessed 2026-02-16)
- Jay Campbell|Nootropic Peptides guide including davunetide overview(accessed 2026-02-16)
- ALZFORUM|Davunetide therapeutics page with clinical trial summary(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Davunetide (NAP/AL-108). The information below is gathered from nootropic forums and Reddit communities. This is not clinical evidence and should not be used as medical guidance.
Davunetide has very limited community usage. Its clinical development for progressive supranuclear palsy failed in a phase 2/3 trial, and the original developer became insolvent. Community interest exists primarily among those interested in neuroprotective strategies, attracted by davunetide's unique microtubule-stabilizing mechanism and its potential for intranasal CNS delivery.
Understanding Protocol Divergence#
Failed Trial Context#
The most important context for davunetide community use is the failed phase 2/3 PSP trial (Boxer et al., 2014). While the compound showed positive results in earlier smaller studies (memory improvement in MCI, functional improvement in schizophrenia), the definitive PSP trial failed. Community users should understand that the evidence trajectory for this compound has been significantly weakened.
Continued Development#
ExoNavis licensed davunetide in 2021 and began a phase 3 trial for ADNP syndrome, a rare genetic neurodevelopmental disorder caused by mutations in the ADNP gene. This represents a targeted application where the mechanism of action is directly relevant to the underlying pathology.
Commonly Reported Outcomes#
Community reports for davunetide are extremely sparse:
- Subtle cognitive effects: A few users report mild improvements in mental clarity, though difficult to distinguish from placebo
- Well-tolerated: No significant side effects reported in the few community accounts available
- Uncertain efficacy: Most community members who have tried davunetide report uncertain or minimal effects
Important Caveats#
- The pivotal clinical trial failed to demonstrate efficacy
- Community doses are lower than clinical doses
- Very few community reports exist
- The compound has limited commercial availability
- Intranasal delivery of reconstituted research peptides differs from pharmaceutical-grade nasal formulations
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Davunetide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.